Page 3 - Mark Cragg News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Scientists gain new insight into how the immune system can be better used to destroy cancer cells Scientists at the University of Southampton's Centre for Cancer Immunology have gained new insight into how the immune system can be better used to find and kill cancer cells. Working with BioInvent International, a team led by Professor Mark Cragg and Dr Jane Willoughby from the Antibody and Vaccine Group, based at the Centre, have shown that antibodies, designed to target the molecule OX40, give a more active immune response when they bind closer to the cell membrane and can be modified to atta...

Credit: NIAID Scientists at the University of Southampton's Centre for Cancer Immunology have gained new insight into how the immune system can be better used to find and kill cancer cells. Working with BioInvent International, a team led by Professor Mark Cragg and Dr Jane Willoughby from the Antibody and Vaccine Group, based at the Centre, have shown that antibodies, designed to target the molecule OX40, give a more active immune response when they bind closer to the cell membrane and can be modified to attack cancer in different ways. OX40 is a 'co-receptor' that helps to stimulate the pr...

Scientists find new way to predict risks of immunotherapy: Here's what you need to know about this cancer treatment The human immune system is constantly working to recognise and eliminate foreign and harmful substances from the body Representational image. News18 In recently published research, a group of scientists from the Uppsala University, Sweden have stated that rituximab, a monoclonal antibody drug that is used for cancer immunotherapy, reacts differently with the blood of healthy people and those with chronic lymphatic l...

 E-Mail IMAGE: Sara Mangso is an Associate senior lecturer/Assistant Professor at the Department of Pharmaceutical Biosciences, Uppsala University view more  Credit: Mikael Wallerstedt In a new study, researchers at Uppsala University have been able to show differences in how Rituximab, a monoclonal antibody drug, interacts with the blood of healthy individuals compared to patients with chronic lymphocytic leukaemia. This has awakened hopes that this analysis method could pave the way for important breakthroughs in immunotherapy research and treatment. Immunotherapy - utilising the ...

New analysis method could pave the way for important breakthroughs in immunotherapy In a new study, researchers at Uppsala University have been able to show differences in how Rituximab, a monoclonal antibody drug, interacts with the blood of healthy individuals compared to patients with chronic lymphatic leukemia. This has awakened hopes that this analysis method could pave the way for important breakthroughs in immunotherapy research and treatment. Immunotherapy - utilizing the body's own immune system to combat tumor cells - is an area in which rapid progress is being made. Many new treatm...